Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003441 | 0.84 | — | — | |
| SCHEMBL1613295 | 0.77 | USP2 (0.50) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL20300385 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL458216 | 0.76 | GPR119 (0.38) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL23387564 | 0.76 | GPR119 (0.38) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL3516214 | 0.76 | ALDH1A1 (0.38) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL2369188 | 0.75 | GPR119 (0.38) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL23151890 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL4282842 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL1108982 | 0.73 | ALDH1A1 (0.39) | ALDH1A1KDM4EUSP2LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | ALDH1A1 2679/4885KDM4E 1007/4885USP2 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.